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Obesity has been a worldwide epidemic for decades. Despite the abundant increase in
knowledge regarding the etiology and pathogenesis of obesity, the prevalence continues
to rise with estimates predicting considerably higher numbers by the year 2030. Obesity is
characterized by an abnormal lipid accumulation, however, the physiological
consequences of obesity are far more concerning. The development of the obesity
phenotype constitutes dramatic alterations in adipocytes, along with several other cellular
mechanisms which causes substantial increase in systemic oxidative stress mediated by
reactive oxygen species (ROS). These alterations promote a chronic state of inﬂammation
in the body caused by the redox imbalance. Together, the systemic oxidative stress and
chronic inﬂammation plays a vital role in maintaining the obese state and exacerbating
onset of cardiovascular complications, Type II diabetes mellitus, dyslipidemia, nonalcoholic steatohepatitis, and other conditions where obesity has been linked as a
signiﬁcant risk factor. Because of the apparent role of oxidative stress in the
pathogenesis of obesity, there has been a growing interest in attenuating the prooxidant state in obesity. Hence, this review aims to highlight the therapeutic role of
antioxidants, agents that negate pro-oxidant state of cells, in ameliorating obesity and
associated comorbidities. More speciﬁcally, this review will explore how various
antioxidants target unique and diverse pathways to exhibit an antioxidant
defense mechanism.
Keywords: obesity, oxidative stress, antioxidants, adipocytes, cardiovascular disease, diabetes

INTRODUCTION
Chronic state of obesity is an ever-growing health concern burdening millions of individuals
worldwide. Characterized physiologically as the accumulation of excess body fat, a substantial
difﬁculty that comes with determining treatment and prevention of the disease is the multifactorial
origin of the etiology (Hruby and Hu, 2015). The complexity of the etiology has led to obesity being
one of the most uncontrollable disease epidemics of the last four decades. Since 1980, the prevalence
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obesity associated phenotype. Hence, this review aims to
independently uncover the potential of several antioxidants in
ameliorating obesity phenotype and associated comorbidities.
Speciﬁcally, this review presents evidence from past literature in
elucidating the role of antioxidants in improving antioxidant
defense mechanism by manipulating localized redox signaling
pathways in an obese state.

of worldwide obesity has doubled with approximately 39% of
people being overweight and 13% obese in 2014, according the
World Health Organization. Further estimations indicate that by
2030, the worldwide obesity could reach 20% (Hruby and Hu,
2015; Mohammed et al., 2018). What is more worrisome is the
increase of early onset obesity in children where obesity and
potential comorbidities persist into adulthood in approximately
50% of cases versus 10% for children without obesity (Fruh,
2017). The stark incline of prevalence across all age groups
is exceedingly concerning when considering the mortality
associated with obesity. Across all age groups, according to
compiled data of 19 cohort studies and 1.46 million
participating individuals, mortality rate generally increased
signiﬁcantly in association with increased body mass index
(BMI) (Berrington de Gonzalez et al., 2010). On average,
obesity can lead to as much as a 5–10 year decrease on life
expectancy (Kuk et al., 2011; Fruh, 2017).
Obesity has been known to be a cause of wide range of
complications due to several underlying pathophysiological
processes. Comorbidities of obesity are diverse and can occur
in many bodily systems including cardiovascular complications,
type 2 diabetes mellitus (T2DM), non-alcoholic steatohepatitis
(NASH), metabolic syndrome, and several other lesser known
morbidities (Sodhi et al., 2015; Srikanthan et al., 2016; Fruh,
2017; Lakhani et al., 2018; Lauby-Secretan et al., 2019). The
trigger for obesity and associated comorbidities is intricately
linked with an increase in reactive oxygen species (ROS) and
subsequent oxidative stress. Several primary sources of
endogenous intracellular ROS have been implicated including
cellular mitochondria, endoplasmic reticulum (ER) stress,
activation of oxidative stress pathways and upregulated activity
of NADPH oxidase (NOX) (Bhatti et al., 2017). This causes a
state of redox imbalance, where the pro-oxidants are excessively
produced and the antioxidant defense mechanisms are
diminished, facilitating a state of chronic inﬂammation
(Fonseca-Alaniz et al., 2007; Wensveen et al., 2015). The
interlinking relation between systemic redox imbalance and
release of inﬂammatory mediators creates an inﬂammatory
milieu affecting the regulation of metabolic pathways,
consequences of which can lead to impaired physiological
functions in obesity and associated comorbidities.
Due to the modulation of redox mechanisms in obesity,
evidence suggests that a multimodal approach to treatment
including diet changes, exercise, and medical treatments may
be successful in curbing oxidant stress (Thompson et al., 2007;
Achkasov et al., 2016). One such considerable approach against
obesity is to counter the cellular pro-oxidant state by ameliorate
the excessive production of ROS and subsequent oxidative stress.
Antioxidants may present a viable therapeutic target to help
ameliorate the negative effects of obesity and oxidative stress on
the physiological systems of the body. The cumulative line of
evidence suggests that antioxidants may modulate dynamic
cellular targets and processes to improve the redox imbalance
in obesity. The mechanisms involved in the regulation of cellular
redox present increasing importance of unraveling the potential
of endogenous and exogenous antioxidants in ameliorating
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OXIDATIVE STRESS IN OBESITY AND
ASSOCIATED COMORBIDITIES
The complex relationship between obesity and the associated
comorbidities involves, ﬁrst, the dysregulation of the vital
communication system that adipocytes have within the body.
Compared to the smaller, healthy adipocytes, the inﬂuence of
obesity is drastic causing a transition to a subset of large,
dysfunctional adipocytes (Lakhani et al., 2018). These larger
adipocytes suffer from poor regulation mechanisms that
disrupt the normal signaling functions that adipocytes play
(Haczeyni et al., 2018). There are over 50 known adipokines
that are released as signaling molecules from adipocytes
including leptin, adiponectin, multiple interleukins, and TNF-a
to name a few (Stolarczyk, 2017). In the obese model, the balance
of these signaling adipokines are signiﬁcantly disrupted. Proinﬂammatory adipokines (IL-6, TNF-a, MCP-1) and leptin,
associated with the maintenance of the obese state, are elevated
during the obese state whereas adiponectin, which plays an
important role in insulin sensitivity, is decreased, connecting
its role to insulin resistance and T2DM (Friedman and Halaas,
1998; Sirico et al., 2018). The increased levels of these proinﬂammatory adipokines place the body into a perpetual state of
inﬂammation, or chronic inﬂammation. During the onset of
obesity, this added inﬂammatory burden and subsequent
adipocyte turnover/remodel to account for the increased fat
accumulation is destructive to the cellular environment.
Macrophages, which are recruited to aid in the adipocyte
turnover, have also been implicated with obesity to potentiate
the subsequent negative effects (Kuroda and Sakaue, 2017).
Following the stark transition to the state of chronic
inﬂammation, the physiological environment quickly becomes
burdened with oxidative stress in the form of increased ROS and
oxidative radicals. One particular cellular component of concern
following initial increase in ROS is at the mitochondrial level.
Mitochondria, when functioning healthily, is already well-known
as a major generator of ROS in the body (Oyewole and BirchMachin, 2015). Invasion of macrophages to remodeling adipose
tissue breaks down older adipocytes which leads to release of
lipid components, inﬂammatory signals, and ROS (Lee et al.,
2010). The continued release of inﬂammatory signals and ROS
from this cycle of apoptosis and remodeling has a harmful
effect on the mitochondria to exacerbate the inﬂammation and
oxidative stress (Dela Cruz and Kang, 2018). ROS plays an
imperative role in facilitating transition of healthy mitochondria
to dysfunctional mitochondria. These dysfunctional mitochondria
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insulin sensitivity in tissues are IL-6 and TNF-a (Stolarczyk,
2017). In addition, IL-10 and adiponectin, two adipokines that
promote insulin sensitivity are decreased in the obese state
(Stolarczyk, 2017). Meanwhile, oxidative stress promotes a
diabetic state by disrupting certain metabolic pathways such as
inhibiting G-3-P dehydrogenase, stimulating buildup of G-3-P,
and up-regulating glycolytic, hexosamine, advanced glycation
end-product (AGE), protein kinase C, and polyl pathways
(Ighodaro, 2018). Despite the speciﬁc mechanisms not being
completely understood, the primary method by which obesity
links to T2DM is through insulin resistance (Burhans et al.,
2018). One proposed mechanism observed over multiple studies
(but not all) is that as adipogenesis takes place, the adipocytes
become dysregulated and release a larger amount of free fatty
acids (FFA) into circulation (Mittendorfer et al., 2009). The FFAmediated insulin resistance involves the products of oxidation of
FFA in tissues which exacerbates already impaired glucose
metabolism (Randle et al., 1965). Several in vitro studies have
revealed a secondary mechanism linking the adipokine, TNF-a,
to insulin resistance by regulating ceramide synthesis (Grigsby
and Dobrowsky, 2001; Hernandez-Corbacho et al., 2015).
Oxidative stress and inﬂammation resulting from obesity is a
systemic problem impacting several regions of the body through
similar mechanisms as seen in T2DM and cardiovascular
complications (Figure 1).

and increased ROS impair the Krebs cycle and respiratory chain
(de Mello et al., 2018). The dysfunctional mitochondria produce
abnormally high amounts of ROS that create a vicious positive
feedback effect on the functional status of the mitochondria
(Wang et al., 2013; de Mello et al., 2018). Although the chronic
inﬂammation induces the state of oxidative stress, dysfunctional
mitochondria are vital for maintaining the diseased state.
Furthermore, brown adipose tissue (BAT) is a mitochondria
rich tissue with high oxidative capacity which have been
implicated in the process of adaptive thermogenesis (LettieriBarbato, 2019). The production of mitochondrial ROS under
thermogenesis is important to maintain the bodily homeostasis,
and this process is ﬁnely controlled through feedback mechanism.
However, in a diseased metabolic condition, there is a shift in the
redox state causing more oxidative stress during thermogenesis.
This shift leads to altered expression of markers associated with
thermogenesis causing an alteration in the adipocyte phenotype
(Lettieri-Barbato, 2019). Studies have demonstrated a causal
relationship between mitochondrial ROS and thermogenesis
using the mitochondria-targeted antioxidant MitoQ, which
efﬁciently ameliorates lipid peroxides and superoxides in vivo
(Rodriguez-Cuenca et al., 2010). It is important to note that the
redox changes occurring in BAT upon thermogenesis are
dynamic, reversible and adapted to by antioxidant pathways
(Chouchani et al., 2017).
This perpetual state of oxidative stress and inﬂammation is what
links obesity to its associated comorbidities. The detrimental role
that this diseased state plays on the cardiovascular system is
substantial. Chronic inﬂammation has a negative effect on
cardiovascular tissue contributing to the associated cardiovascular
disease (CVD) and arteriosclerosis (Libby, 2006). With respect to
obesity, the chronic, low-grade inﬂammation and oxidative from
obesity places the cardiovascular system at an increased risk for
developing plaques in blood vessels and cardiac remodeling (Kachur
et al., 2017). Two studies, one done clinically with patients and the
other in mice on high-fat diet, have shown that increased pressure in
the heart stimulated an increase in function of NADPH oxidase 4
(NOX4), primarily located in the mitochondria of cardiac myocytes
(Kuroda et al., 2010; Munzel et al., 2017). Under states of stress,
NOX4 produces superoxide (O2−) to exacerbate the oxidative stress
of the cardiovascular system (Kuroda et al., 2010). The
inﬂammatory signals released by adipocytes also contribute to
altering the physiology of the heart in obesity. Adiponectin,
downregulated in obesity, plays a protective role in the heart by
stimulating endothelial nitric oxide synthase (eNOS) to maintain
healthy vascular tone. Conversely, the rising leptin levels in the heart
positively correlate with coronary artery disease, left ventricular
hypertrophy, stroke, and myocardial infarction (Soderberg et al.,
1999; Wallace et al., 2001; Chait and den Hartigh, 2020). Along with
pro-inﬂammatory circulating signals, a transcription factor, NF-kB,
is a product of chronic inﬂammation in cardiovascular tissue and is
a useful clinical indicator for obesity-related inﬂammation (de
Almeida et al., 2020).
Insulin resistance and T2DM are also example of diseases
extensively linked as a comorbidity of obesity. A few of the
prominent inﬂammatory adipokines associated with decreasing
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ANTIOXIDANTS IN AMELIORATING
OBESITY AND ASSOCIATED
COMORBIDITIES
Peroxiredoxin
Peroxiredoxins (Prxs) are a family of peroxidase enzymes that
have a highly conserved function to reduce hazardous peroxides
in the body. There are a few different subtypes within the Prx
family, but the mechanism of action of the class as a whole is
mediated through a highly conserved peroxidatic cysteine
residue (CP) (Hall et al., 2009). Despite the fact that the
catalytic function of all Prxs is conserved involving oxidation
of the CP by the peroxide substrate to sulfenic acid, the recycling
of the sulfenic acid back to thiol is the deﬁning feature of the
three classes of Prxs: typical 2-Cys, atypical 2-Cys, and 1-Cys
Prxs (Wood et al., 2003; Rhee, 2016). In the mammalian system,
there are six known peroxiredoxin subtypes including PrxI-IV
(typical 2-Cys), PrxV (atypical 2-Cys), and PrxVI (1-Cys)
(Perkins et al., 2015).
Prxs are widespread across the body, and the subtypes are
localized to several different cellular compartments to play a
universal role against oxidative stress. PrxI and PrxII are both
found predominantly in the cytosol or nuclei of cells with PrxII
playing a vital role in protecting erythrocytes (Rhee et al., 2012).
PrxIII (typical 2-Cys) and PrxV (atypical 2-Cys) are both found
in the mitochondria where they are the primary antioxidant
defense mechanism against the most abundant producer of ROS.
PrxV, however, has also been found in peroxisomes and cytosol
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FIGURE 1 | Schematic representation demonstrating impact of oxidative stress in obesity. Obesity mediates excessive production of ROS which leads to chronic
inﬂammation and altered adipocyte phenotype which further induces several systemic changes causing oxidative stress. Such oxidative stress leads to the
development and progression of chronic diseases such as T2DM, cardiovascular diseases and/or NASH.

aP2, CCAAT/enhancer binding proteins (C/EBPa), and
peroxisomal proliferator activated receptor g (PPARg), and
protein carbonylation. The study also demonstrated decreased
levels of adiponectin, alteration of mitochondrial biogenesis, and
other antioxidant enzymes in mitochondria. The PrxIII KO mice
were identiﬁed to have impaired glucose metabolism and insulin
resistance (Huh et al., 2012). Although the mechanism to how
PrxIII regulates adipocyte function has yet to be established, this
study provides ample data to strongly suggest therapeutic
implications for PrxIII in obesity.
Similarly, recent study also identiﬁed PrxVI as a vital
component leading to an early stage of T2DM with diabetic
dyslipidemia in PrxVI KO mice (Paciﬁci et al., 2014). In the KO
mice, elevated levels of triglycerides and VLDLs were identiﬁed; a
hallmark indicator of adipocyte dysregulation in obesity
(Makhoul et al., 2011). Similarly, the PrxVI KO mice exhibited
increased levels of pro-inﬂammatory cytokines, TNFa, IL-1b, IL10, and IL-6, from adipose tissue. Altogether, this study
exempliﬁes PrxVI in protecting against progression to T2DM
with diabetic dyslipidemia (Paciﬁci et al., 2014). PrxIV is another
subtype implicated in its protective role against diabetes due to
stimulation of enhanced insulin secretion (Mehmeti et al., 2014).
Overall, the mechanisms responsible for mediating the
antioxidant actions of Prxs against obesity are somewhat
undiscovered or undeﬁned due to the relative recency of many
studies involving Prx. However, there is growing evidence
linking some Prx subtypes as key protective mechanisms
against obesity-induced inﬂammation and comorbidities.

(Perkins et al., 2015). PrxIV is the only subtype to be identiﬁed in
the endoplasmic reticulum, which is vital for its antioxidant role
governing protein processing protection (Rhee et al., 2012;
Yamada and Guo, 2018). The only 1-Cys structural subtype is
PrxVI, and this enzyme resides in the cytosolic and lysosomal
compartments in cells (Fisher, 2018).
Because of the highly conserved antioxidant function in
reducing peroxide agents, the extensive bodily coverage of
Prxs allows them to play a signiﬁcant role in obesity-induced
oxidative stress and complications. In mice with PrxV knockout
on high-fat diet, progression to obesity and enhanced
adipogenesis was far more likely than mice without the gene
knockout. Mice with PrxV treatment saw decreased levels of
PPARg and C/EBPa, two markers that indicate an adipogenic
state (Kim et al., 2018; Hammarstedt et al., 2018). Another study
induced hepatic steatosis in a HepG2 cell line with treatment of
FFA to simulate an obese state in vitro. Inducing PrxV
overexpression ameliorated hepatic steatosis progression by
inhibiting lipogenesis associated protein, SREBP-1 and RAS,
and FFA-induced mitochondrial ROS generation (Kim et al.,
2020). A follow-up study in mice revealed that the mechanism
of PrxV in achieving this role appears to be through
phosphorylation of AMPK pathway (Kim et al., 2020). Two
separate studies have also implicated PrxIV and PrxVI in having
a protective role against steatosis by targeting mitochondrial
ROS generation (Yamada and Guo, 2018; Lee et al., 2019).
Another study found that PrxIII was expressed at high levels
in 3T3-L1 mature adipocytes (Huh et al., 2012). Subsequently,
PrxIII knockout (KO) in mice produced a substantial increase in
adipocyte hypertrophy and fat mass compared to wild-type mice.
The PrxIII KO mice were observed to have increased levels
of mitochondrial ROS generation, adipogenic markers,
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N-Acetylcysteine (NAC)
N-Acetylcysteine (NAC) is an antioxidant that serves to reduce
ROS through both direct and indirect effects (Mokhtari et al.,
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2017). The direct effects revolve around its’ ability to react with
hydroxyls, nitrogen dioxide and carbonate (Samuni et al., 2013).
The indirect effects arise from NAC being derived from a
conditionally essential amino acid, L-cysteine and subsequently
provides the cysteine for the formation of glutathione, a wellestablished potent physiological antioxidant (Kerksick and
Willoughby, 2005). However, the oral bioavailability of
glutathione is controversial (Allen and Bradley, 2011; Richie
et al., 2015). Therefore, NAC is marketed as an over-the-counter
oral antioxidant supplement while being utilized in many
treatment protocols and clinical studies with relatively low
adverse effects (Schmitt et al., 2015).
The role of NAC in obesity has yielded promising results
across countless studies. Given that obesity is characterized by
elevated levels of oxidative stress and inﬂammation has made
NAC a profound target for research to minimize the progression
of obesity and associated co-morbidities (Manna and Jain, 2015;
McMurray et al., 2016). Recent in vitro studies have been able to
demonstrate a beneﬁcial role in attenuating biomarkers
associated with adipocyte differentiation pathways such as
PPARg and C/EBPb in 3T3-L1 preadipocyte cells (Calzadilla
et al., 2011). The reduction in these biomarkers was shown
to be equal to glutathione level elevation through NAC
supplementation, reducing ROS, that upregulate the activity of
PPARg and C/EBPb (Lee et al., 2009; Calzadilla et al., 2011; Pratt
et al., 2019). This allows for speculation that supplementation of
NAC during the progression of obesity could reduce
adipogenesis through elevation of glutathione level content.
Furthermore, in vivo studies revealed that supplementation of
NAC in murine models that were fed a high fat diet to induce
obesity, reduced triglyceride and cholesterol content within the
liver by reducing PPARg levels amongst other genes involved in
hepatic storage and metabolism of lipids (Ma et al., 2016).
Studies have given promising evidence that NAC may
normalize levels of hepatic malondialdehyde and superoxide
dismutase (SOD) providing further insight that there could be
a role in preventing obesity associated co-morbidities of the liver
including NASH (Thong-Ngam et al., 2007; Korou et al., 2014).
A major factor revolving around obesity is the oxidative stress
associated inﬂammation present across various metabolic tissues
that has shown to be linked to insulin resistance, atherosclerosis,
and ischemic strokes (Manna and Jain, 2015; Assari and
Bazargan, 2019). The plausible efﬁcacy of NAC in
counteracting obesity associated inﬂammation and apoptosis
that contributes to progression of metabolic disorders is
attributed to NAC’s ability to reduce inﬂammatory cytokines
and apoptotic factors while increasing antioxidant components
(Samuni et al., 2013; de Andrade et al., 2015). These antiapoptotic effects are elicited by the increased levels of SOD,
catalase, glutathione peroxidase and activity of peroxynitrate
which serve to reduce ROS (Zaragoza et al., 2000; de Andrade
et al., 2015). In vitro studies uncovered further contributions to
the reduction of inﬂammation and apoptosis by NAC reducing
levels of vascular cell adhesion molecule 1 (VCAM-1), TNF-a,
IL-6, IL-8, Ikb kinase and subsequent activation of NF-kB, which
have roles in multiple inﬂammatory cascades (Samuni et al.,
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2013; de Andrade et al., 2015; Sun et al., 2019). The capability of
NAC to reduce inﬂammatory pathways and ROS generation may
allow for improvement in insulin sensitivity in obese individuals
that begin to progress to the development of T2DM (Fulghesu
et al., 2002; Lasram et al., 2015; Shen et al., 2018). This was
evidenced by recent studies that revealed treatment with NAC
improved plasma insulin levels, increased insulin sensitivity
across multiple tissues and increased motor activity in murine
models of obesity (Lasram et al., 2015; Shen et al., 2018). The
increase in motor activity could be attributed to NAC’s ability to
improve insulin sensitivity in skeletal muscle tissues as well as
possibly preventing the decline of skeletal muscle sodium
potassium adenosine triphosphatase (Na+/K+ ATPase) activity
allowing for slowed muscle fatigue (McKenna et al., 2006). Both
of these contributions could indicate a theoretical route of
research to determine if any correlation exists between NAC
and increased total daily energy expenditure in obese individuals
which may be combined with proper diet, decreasing the total
degree of inﬂammation by reducing adiposity and fat mass.
Furthermore, NAC was shown to improve insulin sensitivity
and glucose utilization in hyperglycemia induced mice via high
sucrose diet as well as in human volunteers during a
hyperglycemic clamp (Ammon et al., 1992; Diniz et al., 2006).
These studies reinforce the plausible link between NAC and
improving insulin sensitivity to glucose which may provide
insight into improvement of glucose utilization within obese
individuals that have progressed to developing T2DM (Straub
et al., 2019).
The current cumulative line of evidence strongly suggests that
NAC may have a role in being utilized as a cardioprotective agent
by reducing hyperglycemia induced oxidative damage to cardiac
myocytes and cardiac remodeling (Chen et al., 1985; Dludla et al.,
2017). This reduction in oxidative stress attenuates a progressive
loss in cardiac efﬁciency and cardiac ﬁbrosis that would have
progressed to more severe clinical outcomes prior to intervention
(Seddon et al., 2007; Talasaz et al., 2013). Data from multiple
studies indicated that NAC elevated levels of SOD and
glutathione in cardiac myocytes, while reducing levels of TGFb, lipid hydroperoxides and various biomarkers for oxidative
stress (Haleagrahara et al., 2011; Talasaz et al., 2013; Dludla et al.,
2017). Obesity and T2DM both exhibit a characteristic feature of
hypercoagulable states through chronic inﬂammation associated
with obesity and dysregulation of platelet aggregation (Anderson
and Weitz, 2010; Blokhin and Lentz, 2013; Widjaja et al., 2019).
Studies have uncovered that NAC may have a potential role in
reducing the likelihood of thrombus generation through
elevation of platelet glutathione levels and nitric oxide
(Girouard et al., 2003; Martinez de Lizarrondo et al., 2017;
Craver et al., 2020). The elevation in platelet glutathione
ameliorated platelet ROS preventing oxidative constituents to
induce coagulation cascades (Wang et al., 2016). It was also
indicated that NAC may exert antagonistic effects toward Von
Willebrand factor, a necessary component of coagulation
cascades, reducing the risk of thrombosis and stroke (Wang
et al., 2016; Martinez de Lizarrondo et al., 2017). Through
elevating levels of nitric oxide, NAC may have a possible role
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Wong et al., 2017). These beneﬁcial effects elicited by aT are
mediated through the reduction of low density lipoprotein (LDL),
high density lipoprotein (HDL) and total cholesterol levels (Upston
et al., 2003; Kirmizis and Chatzidimitriou, 2009; Wong et al., 2017).
In murine models of diet induced obesity, aT diminished the degree
of hepatic steatosis and circulating triglycerides indicating a
plausible role in the prevention of atherosclerosis and NASH,
associated with obesity (Kawanaka et al., 2013; Alcala et al., 2015).
Cumulative evidence across diabetic individuals, and various animal
models indicate that aT is able to reduce lipid peroxidation within
cellular membranes and reduce overall lipid content in circulation
(Kuznetsov et al., 1993; Wiseman et al., 1995; Eder et al., 2004). This
same reduction of lipids can also be seen within adipocytes as aT
may serve a role in shifting the metabolic proﬁle of obese individuals
toward normalcy. These deviations within adipocytes in obese
individuals compared to non-obese individuals includes an
elevation of matrix metalloproteinase activity and collagen
deposition (Sun et al., 2013; Lauhio et al., 2016). The
accumulation of collagen prevents adipocyte expansion and may
contribute to the phenotype and inﬂammation seen in obesity (Unal
et al., 2010; Jaoude and Koh, 2016; Lin et al., 2016; Wong et al.,
2017). However, supplementation with aT promoted adipocyte
differentiation and expansion indicating that aT may play a role in
downregulating pathways associated with collagen accumulation
and abnormal adipocyte growth to attenuate the pathogenic obesity
phenotype (Kim et al., 2007).
Cumulative studies have indicated that aT supplementation
reduces biomarkers of lipid peroxidation in T2DM patients and
improve insulin sensitivity (Wu et al., 2007; Thalhamer et al.,
2008; Murer et al., 2014; Niki, 2015). The elevation in insulin
sensitivity may be attributed to the anti-inﬂammatory action of
aT in visceral adipose tissue, by reducing the level of p38
phosphorylation, which is associated with many inﬂammatory
responses and insulin resistance (Wu et al., 2007; Wong et al.,
2017). Through scavenging of ROS, aT may serve to ameliorate
the impact that persistent hyperglycemic conditions have on
promoting ROS production and inﬂammatory cascade activation
(Alcala et al., 2015; Wong et al., 2017). Thus, there may be a role
linking aT’s effects on inﬂammatory cascades that may lead to
the attenuation of the diabetic phenotype (Lee et al., 1999).
The actions of aT have shown to attenuate production of
ROS and activity of protein kinase C (PKC) pathways associated
with cellular cascades that promote proliferation and
differentiation (Martin-Nizard et al., 1998). These cascades
have shown to be affected by aT through increasing the
expression of biological compounds that inhibit PKC resulting
in the downregulation of a multitude of cascades (Engin, 2009).
Among these cascades, aT exhibits an inhibitory effect on the
proliferation of vascular smooth muscle cells that may contribute
to CVD diseases such as atherosclerosis (Nakashima et al., 1998),
indicating that aT may have a plausible role in cardio protection
(Engin, 2009; Rizvi et al., 2014). Evidence has highlighted that aT
serves a role in cardioprotective mechanisms through prevention
of retinal vascular disease in hyperglycemic states associated with
T2DM patients by inhibition of these PKC mediated pathways
(Engin, 2009). aT may also serve to attenuate platelet

in regulation of high blood pressure in obese individuals via
nitric oxide mediated vasodilation (Zicha et al., 2006; Gibson
et al., 2011). NAC’s cardioprotective abilities also correlate to its
ability to reduce the expression of malic enzyme, fatty acid
synthase and other enzymes involved in biosynthesis of
triglyceride and cholesterol biosynthesis pathways (Lin and
Yin, 2008; Korou et al., 2010; Korou et al., 2014; Ma et al.,
2016). This cardioprotective ability may indicate that NAC may
play a role in prevention of atherosclerosis.

Vitamin E
Vitamin E (VitE) primarily describes a group of eight compounds
known as tocopherols and tocotrienols where each group consists of
a, b, g, and d tocopherol/tocotrienol compounds (Colombo and
vitamin, 2010; Rizvi et al., 2014). Each of the eight compounds, has
shown to elicit some degree of antioxidant properties. However, of
all the compounds the constituent a-tocopherol (aT) possesses the
highest physiological concentrations (Baxter et al., 2012). It has been
shown extensively that aT acts as an antioxidant through its
chromanol ring, allowing it to scavenge and remove ROS
preventing oxidative damage (Ahsan et al., 2015). Through their
lipophilic characteristics, aT serves to protect polyunsaturated fatty
acids present in membrane phospholipids and lipoproteins to
stabilize cellular membranes (Kuznetsov et al., 1993; Wallert et al.,
2014; Galmes et al., 2018). Many studies have suggested a positive
correlation between aT and attenuating inﬂammation, clinical
disorders and promoting immune system functionality (Galmes
et al., 2018; Lewis et al., 2019). This research along with VitE being
widely available, obtained solely from the diet particularly from
vegetable oils, has peaked interest into incorporating aT
supplementation into many treatment protocols of various clinical
disorders including metabolic syndrome where individuals are
shown to have lower levels of aT (Montonen et al., 2004;
Mehmetoglu et al., 2011). This may indicate that the development
and progression of obesity related metabolic syndrome could in
part be attributed to reduced levels of aT (Lira et al., 2011).
Recent in vivo studies in models of obesity and human studies
have indicated that aT supplementation was capable of attenuating
inﬂammatory processes by reducing the expression of IL-6, TNF-a,
malondialdehyde and C reactive protein while increasing
antioxidant constituents (Patrick and Uzick, 2001; Wong et al.,
2017). Furthermore, aT may also act to inhibit pathways that are
activated by ROS such as p38 MAPK (Schett et al., 2008; Thalhamer
et al., 2008; Wang et al., 2011; Wong et al., 2017). These pathways
tend to be elevated in obese individuals, various inﬂammatory
pathologies and are diminished with aT supplementation (Wong
et al., 2017; Donohoe et al., 2020). Administration of aT in obese
individual induces differentiation of macrophages toward an M2
phenotype that exhibits anti-inﬂammatory effects (Alcala et al.,
2015; Ray et al., 2016). Thus, aT may have a plausible role in
reducing inﬂammation mediated by ROS-induced oxidative
damage and exert effects on immune system functionality (Lee
and Han, 2018).
The ability of aT to reduce total cholesterol and triglycerides has
yielded promising results in metabolic syndrome patients and in
prevention of obesity associated atherosclerosis (Upston et al., 2003;
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aggregation, stimulate prostacyclin release, and elevate nitric
oxide synthase (Rizvi et al., 2014). Moreover, aT reduced the
systolic blood pressure through increasing nitric oxide synthase
activity in murine models of hypertension (Tran and Chan, 1990;
Rizvi et al., 2014). Thus, the elevation of prostacyclin and
nitric oxide synthase uncovers a plausible cardioprotective
mechanism against hypertension as both are potent
vasodilators (Moncada and Vane, 1979; Ahmad et al., 2018).
Evidence accumulated across in vitro studies suggest that aT
may lower the levels of TNF-a induced stimulation of
intracellular cell adhesion molecule (ICAM-1) and VCAM-1
(Kirmizis and Chatzidimitriou, 2009; Cook-Mills et al., 2013;
Cook-Mills, 2013; Rizvi et al., 2014). This downregulation may
indicate diminished platelet aggregation and plausible reduction
in the risk for atherosclerosis and thrombosis (Nakashima et al.,
1998; Rizvi et al., 2014).

2004; Pae and Chung, 2009). Biliverdin may also regulate its antiinﬂammatory actions through multiple mechanisms that involve
the inhibition of NF-kb and enhancing production of antiinﬂammatory constituents (Pae and Chung, 2009). The free
iron that is released from heme degradation possess
inﬂammatory and cytotoxic characteristics (Dutra and Bozza,
2014). However, to compensate for the elevation in free iron
from heme degradation, HO-1 upregulates ferritin synthesis that
is capable of storing free iron preventing possible initiation of
otherwise harmful inﬂammatory cascades (Balla et al., 1992; Pae
and Chung, 2009). Through the suppression of proinﬂammatory mediators and antioxidant actions, HO-1 and
the products of heme degradation are able to reduce
inﬂammation and possibly diminish the phenotypic expression
associated with obesity.
Through the reduction in proinﬂammatory mediators
directly and indirectly, HO-1 may contribute to improving
insulin sensitivity in diabetics, reducing adipogenesis and the
probability of CVD development. Recent studies indicate that the
reduced adipogenesis and adipocyte dysfunction may be
attributed to the regulation of HO-1 mediated Wnt/b-catenin
pathways that act to reduce expression of PPARg and C/EBPa
(Siersbaek et al., 2010; Cao et al., 2012; Khitan et al., 2014).
Biliverdin, produced via HO-1 degradation of heme, may
contribute to normalizing adipocyte function by exerting
regulatory effects on PKC pathways (Wegiel and Otterbein,
2012; Khitan et al., 2014). By limiting adipogenesis, adipocyte
proliferation and differentiation, HO-1 is able to reduce the
inﬂammatory response within adipocytes promoting a more
stable microenvironment (Cao et al., 2012; Wagner et al.,
2017). This is due to smaller adipocytes being more responsive
to insulin and release higher concentrations of adiponectin
compared to larger adipocytes (Peterson et al., 2019). The
improvement of insulin action can be attributed to the effects
of HO-1 attenuating the expression of insulin resistance
mediators including TNF-a, IL-1b and increasing the levels of
adiponectin (Kim et al., 2008; Burgess et al., 2010; Cao et al.,
2012). Adiponectin is a hormone that is released from
adipocytes, that possesses anti-inﬂammatory characteristics
and confers insulin sensitivity (Li et al., 2008). The actions of
adiponectin resemble those of HO-1, that decreases the
expression of TNF-a, IL-1b, NF-kb signaling as well as other
inﬂammatory mediators to subvert this pathological phenotype
(Kim et al., 2008; Burgess et al., 2010; Aprahamian and Sam,
2011). Furthermore, adiponectin and HO-1 both serve to act on
inhibiting AMPK pathway, which is profound in obesity
associated inﬂammation (Hosick and Stec, 2012; Sodhi et al.,
2015; Smith et al., 2016; Achari and Jain, 2017). By inducing
adiponectin upregulation, HO-1 is able to work in concert with
adiponectin involving AMPK cascades to improve insulin
sensitivity, attenuate adipogenesis and progression of NASH
(Burgess et al., 2010; Hwang et al., 2013; Sodhi et al., 2015;
Smith et al., 2016; Peterson et al., 2019).
Further elucidating the importance of HO-1 in CVD
associated with obesity is the therapeutic use of statins that
have been shown to promote the induction of HO-1 to prevent

Heme Oxygenase-1
Heme oxygenase-1 (HO-1) has been established as a stressinducible enzyme that possesses cytoprotective, antiinﬂammatory and antioxidant properties (Nath, 2006; Araujo
et al., 2012). Other functions include its role in the rate limiting
step for heme degradation as it exerts an indirect antioxidant
effect in this manner through the degradation products (Nath,
2006). Heme is a potent pro-oxidant that serves to increase
production of ROS seen in many pathological states (Wu et al.,
2019). HO-1 degrades heme through a series of catabolic steps
that yield products including biliverdin, carbon monoxide (CO)
and free iron (Gozzelino et al., 2010). These effects have sparked
interest into multitudes of studies for incorporation into
therapeutic regimens for a plausible impediment of disease
progression in various inﬂammatory diseases, CVD and
metabolic dysregulation associated with obesity (Durante,
2003; Pae and Chung, 2009; Bereczki et al., 2018).
The importance of functioning HO-1 has been shown by in
vivo HMOX1 gene KO murine models (Poss and Tonegawa,
1997; Chan et al., 2011; Ayer et al., 2016). Studies have shown
that induced deﬁciency of HO-1 results in chronic inﬂammatory
states with elevated levels of pro-inﬂammatory cytokines that are
similar to the levels in various inﬂammatory diseases (Poss and
Tonegawa, 1997; Chan et al., 2011; Lenoir et al., 2017). The antiinﬂammatory effects elicited by HO-1 under normal conditions
can be attributed to its ability to degrade free heme. In excess,
free heme has the capability to contribute to the pathology of
various inﬂammatory diseases through destabilizing cellular
membranes, damaging organelles and DNA (Kumar and
Bandyopadhyay, 2005; Sparkenbaugh et al., 2015). Biliverdin,
CO and free iron produced from degradation of heme have been
shown to elicit anti-inﬂammatory actions through a variety of
different cascades (Peterson et al., 2020). CO is able to reduce
pro-inﬂammatory cytokines attributing to the toxicity of free
heme including TNF-a, IL-1b and IL-2 through its actions on
MAPK and NF-kb pathways (Kruger et al., 2006; Wang et al.,
2009; Burgess et al., 2010; Paine et al., 2010; Chan et al., 2011).
This reduction in IL-2 may contribute to most of the antiproliferative actions associated with CO signaling (Pae et al.,
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high sucrose with cranberry extract revealed that polyphenols
lowers total weight gain, visceral adipose tissue weight, hepatic
triglyceride accumulation, and plasma cholesterol levels (Anhe
et al., 2015). Also, mice given cranberry extract had similar
fasting glycaemia but with lower fasting insulinaemia, which
implies that polyphenols accentuate insulin sensitivity (Anhe
et al., 2015). In addition to cranberry extract, the polyphenols
present in pomegranate extracts have also been reported to
prevent and treat obesity. Previous studies have reported that
the pomegranate extract could decrease the level of lipids in the
blood with signiﬁcant anti-inﬂammatory activities. Recent in
vitro study has also demonstrated that the polyphenols contained
in pomegranate extracts in combination with probiotics induces
synergistic effects that substantially reduces the triglyceride levels
and intracellular lipid increase (Sorrenti et al., 2019). The study
showed that in vitro treatment with pomegranate extract and
probiotics improved the expression of fatty acid synthase,
adiponectin, adipogenic markers, PPARg and SREBP, as well
as inﬂammatory cytokine, IL-6.
Parallel to the availability of cranberry polyphenols,
resveratrol is found in red wine and it undergoes rapid
metabolism in the small intestine and by the gut microbiota,
leading to low plasma bioavailability and complex outcomes
(Galiniak et al., 2019). Resveratrol has been shown to increase
endurance during exercise by expanding air capacity and oxygen
consumption and also increase insulin sensitivity of visceral
white adipose tissue in mice (Springer and Moco, 2019).
Consumption of resveratrol alters the composition of gut
microbiota by increasing symbiotic bacteria like Bacteroidetes
and decreasing opportunistic pathogens like Escherichia coli. The
favorable stimulation of Bacteroidetes by resveratrol decreases
the levels of trimethylamine-N-oxide (TMAO), which is
associated with chronic diseases like obesity (Schugar et al.,
2017). A fecal transplant of resveratrol-fed mice to obese mice
improved their glucose homeostasis. Another study
demonstrated that resveratrol’s protein interaction stimulates
mitochondrial biogenesis and increases the use of lipids while
decreasing glycolysis in the muscle and liver by the deacetylation
of PGC1a, leading to an increase in energy expenditure (Lagouge
et al., 2006). Concomitantly with protein interactions, resveratrol
increases lipolysis and decreases adipogenesis by the inhibition of
PPARg and SIRT1 (Houtkooper et al., 2012). Resveratrol’s
function as an antioxidant in redox cycling leads to the
activation of Nuclear factor-erythroid 2-related factor-2 (Nrf2),
increase in SOD, and reduction in BMI, blood pressure and body
weight (Springer and Moco, 2019).
Recent advances have suggested the beneﬁcial role of
curcumin, a polyphenol antioxidant, in ameliorating obesity
phenotype. In vitro evidence suggests the ability of curcumin
in the browning of white adipocytes by increasing the protein
levels of hormone-sensitive lipase and p-acyl-CoA carboxylase,
augmenting lipolysis (Lone et al., 2016). Curcumin has been largely
implicated in attenuating insulin resistance, hyperglycemia,
hyperlipidemia and comorbidities associated with obesity
(Aggarwal, 2010). The cumulative line of evidence suggest that
curcumin can modulate various targets involved in obesity and

atherosclerosis (Heeba et al., 2009). The ability of HO-1 to
reduce ROS and pro-oxidant constituents diminishes the risk
for oxidation of LDL providing cardioprotective mechanisms
against generation of atherosclerotic plaques (Cheng et al., 2009).
These plaques elicit higher levels of HO-1 induction that can
likely be attributed to physiological response to prevent plaque
progression, thrombus generation and activation of
inﬂammatory cascades in vascular endothelium (Cheng et al.,
2009; Durante, 2011). Moreover, HO-1 may attenuate vascular
inﬂammation by reducing VCAM levels, apoptotic factors,
release of inﬂammatory mediators from mast cells and
upregulating anti-apoptotic factors (Takamiya et al., 2002;
Kruger et al., 2006; Chan et al., 2011). The cardioprotective
mechanisms provided through induction of HO-1 may be
attributed to not only the direct actions of HO-1 but also the
indirect actions mediated through heme degradation products
CO and biliverdin (Chan et al., 2011; Hosick and Stec, 2012; Ayer
et al., 2016). CO may activate soluble guanylyl cyclase cascades
leading to vascular relaxation and diminishing platelet
aggregation to prevent subsequent thrombus formation
(Furchgott and Jothianandan, 1991; Cheng et al., 2009; Hosick
and Stec, 2012; Ayer et al., 2016). The actions of CO and
biliverdin also seem to mediate pathways acting on vascular
smooth muscle cell proliferation in response to injury associated
from the pathological microenvironment produced from obesity
mediated inﬂammatory responses (Ollinger et al., 2005; Beck
et al., 2010). Through the actions of CO and biliverdin, HO-1
inhibitory effect may attenuate the development and progression
of multiple vascular diseases associated with metabolic syndrome
and obesity (Frismantiene et al., 2018). The plausible
contribution of HO-1 in prevention of CVD, NASH, insulin
resistance, inﬂammation, apoptosis, oxidation and adipogenesis
provide insight into the importance of utilizing HO-1 and
associated pathways in therapeutic regimens to reduce the
morbidity and mortality associated with obesity phenotypes.

Polyphenols
Polyphenols are a type of antioxidants that are commonly found
in diets such as cranberries, red wine, green teas, and many
others (Fraga et al., 2019). Although the direct mechanism of
action of polyphenols is not well understood, many studies have
shown that polyphenols attenuates the obesity phenotype and
related comorbidities. Polyphenols has been shown to affect the
gut microbiota and stimulate signaling pathways that promote
fatty acid b-oxidation, mobilization of adipose tissue through
lipolysis, lowering of body weight and fat mass by increasing fat
use and energy expenditure through thermogenesis induction,
adipose apoptosis, satiety, and an increase in basal metabolic rate
(Castro-Barquero et al., 2018). Polyphenol’s inhibitory actions
include the downregulation of adipose differentiation and
adipogenesis, buildup of triglyceride, and chronic obesityrelated inﬂammation.
Cumulative lines of evidence have demonstrated the
beneﬁcial role of polyphenol, found in cranberry extract, to
improve diet induced obese phenotype in murine model. The
study comparing a diet with high fat/high sucrose and high fat/
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FIGURE 2 | Schematic representation demonstrating the beneﬁcial role of antioxidants in modulating obesity phenotype. Obesity mediates excessive ROS
production and inﬂammation which is further exacerbated by altered mitochondrial biogenesis and activation of macrophages from dysfunctional adipocytes.
The antioxidant defense mechanism scavenges ROS and ameliorates obesity phenotype.

gluconeogenesis in the liver in murine models (Li et al., 2018).
EGCG further attenuates the diabetic phenotype by improving
the wound healing process through lowering of macrophage
accumulation and inﬂammation (Zhang et al., 2018). When
treated with EGCG, insulin resistance along with adipose
differentiation is also lowered (Khan and Mukhtar, 2018). In
the context of lipid metabolism, EGCG stimulates b-oxidation
and lipolysis and downregulates lipogenic enzymes and lipid
emulsiﬁcation (Huang et al., 2014).

metabolic diseases including, suppression of NF-kB and its
regulation inﬂammatory cytokines (Singh and Aggarwal, 1995),
IKK (Aggarwal et al., 2006), JNK (Wang et al., 2009). Studies in
murine models also demonstrated the effectiveness of dietary
curcumin in lowering triglycerides, cholesterol and phospholipid
levels (Rao et al., 1970; Babu and Srinivasan, 1997). Apart from
that, bergamot has also been shown to illicit antioxidant
properties and ameliorate obesity and associated comorbidities.
Bergamot is rich with ﬂavonoids and phenolic compounds that
have been shown to improve dyslipidemia and systemic
inﬂammation in patients with metabolic syndrome (Musolino
et al., 2019). The mechanistic action of bergamot is mediated by
its compounds, bruteridin and melitidin, which bind the catalytic
site of HMG-CoA reductase causing inhibition of cholesterol
synthesis by replacing its endogenous substrate HMG-CoA
(Leopoldini et al., 2010). The antioxidant property of bergamot
also stimulates the growth of beneﬁcial gut microbiota. Studies
have provided preclinical proof of concept that induction of
bergamot may improve the phenotypical and morphological
features of NASH along with reduction in adipose tissue
inﬂammation and inﬂammatory cytokines, IL-6 and TNFa,
hypoadiponectinemia, insulin resistance and dyslipidemia
(Musolino et al., 2020).
Epigallocatechin-3-gallate (EGCG) found in green tea is the
most dominantly studied catechin. Although EGCG is known for
its anti-cancer effects, studies have demonstrated a signiﬁcant
role in ameliorating diabetes. In the context of T2DM, EGCG
promotes glucose homeostasis and inhibits lipogenesis and
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Carotenoids
Carotenoids are 40-carbon molecules found in red, yellow, and
orange fruits and vegetables and are subdivided into carotenes
and xanthophylls (Langi et al., 2018). Carotenes differ in
structure from xanthophylls by the absence of oxygen groups,
while xanthophylls may have multiple oxygen groups and are
more soluble in water (Moran et al., 2018). The complexity of
their actions on lipid membranes is due to its unique action of
each carotenoid to various compositions of membranes (Johnson
et al., 2018). In the small intestine, carotenoids are emulsiﬁed
into micelles and their absorptions are facilitated by cell surface
proteins (Bohn et al., 2017). After absorption, carotenoids are
packaged into chylomicrons for transport to the liver and then
released into blood. Carotenes are usually packaged into LDL,
while xanthophylls are typically packaged into HDL (Wang et al.,
2007). Both types of carotenoids are known for their functions in
vision, but growing evidence suggests their anti-obesity activities
(Coronel et al., 2019).
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TABLE 1 | Summary of mechanistic action of antioxidants in ameliorating obesity phenotype and associated comorbidities.
Antioxidant

Peroxiredoxin

Source

Endogenous Enzyme

Pathway/Mechanism

Inhibition of PPARg and C/
EBPa

Phosphorylation of AMPK

Anti-Obesity
Phenotype and
Related
Comorbidities

Adiponectin
Insulin sensitivity
Adipogenesis
Protein

References

(Huh et al., 2012; Mehmeti et al., 2014; Paciﬁci et al., 2014;
Hammarstedt et al., 2018; Kim et al., 2018; Yamada and Guo,
2018; Lee et al., 2019; Kim et al., 2020)

carbonylation
Fatty acid
oxidation
SREBP-1

FAS
Lipid
Inhibition of IL-6, IL-10,
and TNFa
NOver-the-counter oral
Acetylcysteine supplement

Inhibition of PPARg and C/
EBPb
Inhibition of NFkB

accumulation
Insulin secretion

Diabetes
Dyslipidemia
Lipolysis
Adipogenesis
NAFLD/NASH
 Insulin sensitivity
 Inﬂammatory

(Girouard et al., 2003; McKenna et al., 2006; Carlsen et al., 2009;
Calzadilla et al., 2011; Haleagrahara et al., 2011; Schmitt et al.,
2015; Ma et al., 2016; Pratt et al., 2019; Sun et al., 2019)

cascades
Promotes skeletal muscle
Na+/K+ ATPase activity
Activates cardiac
Superoxide dismutase and
glutathione
Upregulates platelet
glutathione and Nitric
Oxide
Downregulates malic
enzyme and fatty acid
synthase

Vitamin E

Vegetable oils, wheatgerm,
sunﬂower, soybean, walnut,
over-the-counter oral
supplement

Destabilizes Von
Willebrand Factor
Downregulates IL-6, TNFa, malondialdehyde and creactive protein
Inhibition of p38 MAPK
pathways

 Motor activity
 Cardiac
efﬁciency
 Cardiac ﬁbrosis
 Vasodilation
 Thrombogenicity
 Lipogenesis

Cholesterologenesis
 Thrombogenicity

 Insulin sensitivity
 Inﬂammatory

(Boscoboinik et al., 1991; Cook-Mills, 2013; Alcala et al., 2015;
Lin et al., 2016; Wong et al., 2017; Lee and Han, 2018)

cascades

 Insulin sensitivity
 Adipogenesis
 Inﬂammatory
cascades

 Oxidative

Upregulates M2
macrophage phenotype
Inhibition of PKC pathways

cascades
 Collagen
deposition and
ﬁbrosis
 Inﬂammatory
response
 Vascular disease

 Thrombogenicity
 Inﬂammatory
cascades
Upregulates nitric oxide
 Vasodilation
synthase and prostacyclins
Downregulates LDL, HDL
Lipid Mobilization
and cholesterologenesis
 Vascular disease
(Continued)
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TABLE 1 | Continued
Antioxidant

Source

Pathway/Mechanism

Downregulates ICAM-1
and VCAM-1
Downregulates Matrix
Metalloproteinases

Anti-Obesity
Phenotype and
Related
Comorbidities

References

 Hepatic
steatosis
 Vascular disease
 Thrombogenicity
Adipocyte
expansion
 Insulin sensitivity

 Inﬂammatory
response
Heme
Oxygenase–1

Endogenous enzyme

Degrades free heme

Inhibits MAPK, NF-kb,
PKC

 Liberation of CO
and Biliverdin
 Inﬂammatory
response
 Oxidative
cascades
 Vasodilation

(Burgess et al., 2010; Gozzelino et al., 2010; Chan et al., 2011;
Cao et al., 2012; Sodhi et al., 2015; Peterson et al., 2020)

 Inﬂammatory
response

Upregulates ferritin
synthesis
Inhibition of PPARg and C/
EBPa
Downregulates TNF-a, IL1b, IL-2

Adipogenesis
 Thrombogenicity
 Inﬂammatory
response

Lipolysis
Adipogenesis
 Insulin sensitivity
 Inﬂammatory
response

Upregulates adiponectin

 Insulin sensitivity
 Inﬂammatory
response

Reduces oxidized LDL,
VCAM-1, mast cell
degranulation
Upregulates AMPK
cascades

 Adipogenesis
 Vascular disease
 Inﬂammatory
response

Lipid Mobilization
 Insulin sensitivity
 Vascular disease
 Hepatic
steatosis
 Lipogenesis

Activates soluble guanylyl
cyclase
Polyphenol

Cranberry, red wine, green tea, Deacetylation of PGC1a
pomegranate extract,
curcumin, bergamot

Inhibition of PPARg and
SIRT1
Activation of Nuclear
factor-erythroid 2-related
factor-2 (Nrf2)

 Vasodilation
 Thrombogenicity
Mitochondrial
Biogenesis
Lipid Mobilization

(Lagouge et al., 2006; Houtkooper et al., 2012; Fraga et al.,
2019; Springer and Moco, 2019)

Energy
expenditure
Lipolysis
Adipogenesis
Superoxide
dismutase
Body Mass Index

Blood pressure
Weight
(Continued)
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TABLE 1 | Continued
Antioxidant

Carotenoids

Superoxide
Dismutase

Source

Red, yellow, and orange fruits
and vegetables

Endogenous Enzyme

Pathway/Mechanism

Inhibition of PPARg
Upregulates uncoupling
protein-1 (UCP-1) and b3adrenergic receptor
(Adrb3)
Inhibition of PPARg,
PPARa, FIAF
Decreases levels of
Carnitine Palmitoyl
Transferase and Fatty Acid
Synthase
Inhibition of ERK1/2 and
NF-kB

Anti-Obesity
Phenotype and
Related
Comorbidities

Adipogenesis
Thermogenesis
Lipid Mobilization
Energy

References

(Schwarz et al., 1997; Maeda et al., 2005; Langi et al., 2018)

expenditure
Weight loss

Lipolysis
Adipogenesis
 Lipogenesis

(Hennig et al., 2006; Samuni et al., 2010; Perriotte-Olson et al.,
2016)

 Inﬂammatory
cascades

This table summarizes the source of each antioxidant along with the mechanism that is modulated with the supplementation of each antioxidant. The mechanistic action of each antioxidant
results in amelioration of obesity phenotype and characteristics associated with it. The green arrow () represents upregulation and red arrow () represents downregulation of
phenotypical characteristics of obesity in response to antioxidants.

Studies have demonstrated the roles b-carotene play in
adipose differentiation as a vitamin A precursor. b-carotene is
cleaved by b-carotene oxygenase 1 (BCO1) into retinal and then
rapidly metabolized to transcriptionally active retinoic acid,
which is a type of vitamin A (von Lintig, 2012). In cell culture
models, retinoic acid inhibits the expression of adipogenic
transcription factors like PPARg, leading to a decrease in
adipogenesis (Schwarz et al., 1997). A rat study demonstrated
that vitamin A reduce obesity, but only when supplemented to
rats with mature adipocytes. When vitamin A was administrated
in newborns, adipocyte proliferation was promoted, while
supplementation to mature adipocyte led to loss of weight
(Coronel et al., 2019). Relatedly, a human study with 29,000
participants revealed that elevated serum b-carotene levels are
associated with lower cardiovascular and heart disease (Huang
et al., 2018). Other human studies have demonstrated that higher
b-carotene is associated with lower incidence of metabolic
syndrome (Beydoun et al., 2019) and lower body weight (Berry
et al., 2012) (PMID: 22396202). An analogous study showed that
higher serum levels of b-carotene are related to lower BMI and
subcutaneous adipose tissue in children (Canas et al., 2017).
Similar to carotenes, xanthophylls like fucoxanthin found in
seaweed elicit physiological effects against the obesity phenotype
and related diseases. Fucoxanthin is processed into fucoxanthinol in
the gastrointestinal tract and then amarouciaxanthin A in the liver
(Asai et al., 2004). The proportion of the metabolites of fucoxanthin
differ in that more fucoxanthiol is found in the visceral organs like
the lungs, heart, and kidneys, while amarouciaxanthin A is more
preferentially found in adipose white tissue (Hashimoto et al., 2009).
In vivo study with fucoxanthin and its metabolite’s actions against
the characteristics associated with obesity, demonstrated reduction
of serum and hepatic levels of triglycerides and inﬂammatory
cytokines like PGE2, nitric oxide, IL-1, and TNF-a (Sakai et al.,
2009; Hu et al., 2012). The study also demonstrated an increase in
HDL levels, while LDL receptor levels decreased (Beppu et al.,

Frontiers in Pharmacology | www.frontiersin.org

2012). Furthermore, the administration of fucoxanthin led to
decrease in both mRNA expression of fatty acid synthase and
blood leptin levels (Beppu et al., 2013). Further studies have
shown that fucoxanthin upregulates uncoupling protein-1 (UCP1) in white adipose tissue and b3-adrenergic receptor (Adrb3),
leading to increased thermogenesis, fatty acid oxidation, energy
expenditure, and weight loss (Maeda et al., 2005). Fucoxanthinol
and amarouciaxanthin accentuates these anti-obesity actions of
fucoxanthin in later stages of adipocyte differentiation by
suppressing PPARg expression and glucose uptake (Kang
et al., 2011).

Superoxide Dismutase
Various forms of mammalian SOD are characterized by where
the enzyme is found and what metal it is catalyzed by. SOD1 and
SOD3 are associated with copper and zinc, while SOD2 requires
manganese (Zelko et al., 2002; Fukai and Ushio-Fukai, 2011).
Despite the differing compartmentalization of each forms of
SOD in the mitochondria, cytoplasm and extracellular matrix,
they all share the function of neutralizing ROS (Miao and St
Clair, 2009). Since all SODs are endogenous enzymes, SOD
murine trials are conducted through mimetics like 4-Hydroxy2,2,6,6-tetramethylpiperidine-N-oxyl (tempol), nanoformulated
SOD (NanoSOD), and hydrodynamic injections of SOD3
plasmids. Although SODs are known for their essential role in
handling oxidative stress, recent studies suggest a crucial role in
ameliorating the obesity phenotype.
Mimetics of SOD have been shown to attenuate the obesity
phenotype. Recent in vivo study demonstrated that mice
supplemented with tempol in their diet weighed less than
control mice (Samuni et al., 2010). In parallel, a recent study
demonstrated that in vivo treatment of NanoSOD in high fat diet
fed mice improved the levels of plasma triglyceride, liver
triglyceride, and hepatic lipid accumulation (Perriotte-Olson
et al., 2016). The anti-obesity effects of SOD were demonstrated

12

August 2020 | Volume 11 | Article 1234

Tun et al.

Antioxidants Ameliorate Obesity Phenotype

when mice received hydrodynamic injections of SOD3 plasmids
(Cui et al., 2014). The mice induced with SOD3 showed
improvement in body weight which was similar to mice fed a
regular chow, as compared to high fat diet fed mice (Cui et al.,
2014). Concomitantly, the administration of SOD3 led to smaller
epididymal, inguinal, and perirenal white adipose tissues in
comparison to the same diet without SOD3 (Cui et al., 2014).
Furthermore, the study showed that mice fed a high fat diet with
adenoviral SOD3 vectors had lower liver weight, levels
of triglycerides, cholesterol by weight, and quantity of nonesteriﬁed fatty acids, compared to mice fed a high fat diet (Cui
et al., 2014). The study provided a conclusive evidence that the
induction of SOD3 improved glucose tolerance and insulin
resistance in high fat diet fed mice (Cui et al., 2014).
Several studies have demonstrated that SOD analogs have
anti-obesity effects in the molecular level by inﬂuencing
metabolic pathways and related enzymes. In a cell culture of
adipocytes, tempol lowered the cellular level of PPARg and
PPARa, and this led to the downregulation of fasting-induced
adipose factor (FIAF) (Samuni et al., 2010). PPARg and PPARa
positively regulate FIAF in the liver and skeletal muscle during
the fasted state and can lead to adipogenic outcomes (Dutton and
Trayhurn, 2008). In a similar study, mice administered with
NanoSOD had markedly decreased levels of fatty acid metabolic
enzyme Carnitine Palmitoyl Transferase and a lipogenic de novo
enzyme fatty acid synthase (Perriotte-Olson et al., 2016). This
study also revealed the downregulation of the ERK1/2 signaling
pathway by NanoSOD. The ERK1/2 pathway can lead to obesitylinked inﬂammation by the activation of NF-kB (Hennig et al.,
2006). In conjunction, the levels of CPT1a, CPT1b, PGC1a,
PGC1b, and UCP2, which are mRNA genes associated with
energy expenditure and lipolysis, were higher when mice were
given SOD3 (Cui et al., 2014).
Inﬂammation by itself or caused by excess macrophage is
intricately linked with obesity, and the induction of SODs
alleviates these outcomes. Studies have shown that mice fed a
high fat diet and administered NanoSOD, showed improvement
in obesity-related macrophage accumulation levels and
inﬂammatory markers like TNFa, MCP1, and MMP12 improved
(Perriotte-Olson et al., 2016). In a related study, mice that were fed a
high fat diet had crown-like signs of macrophage inﬁltrations, while
mice that were given a high fat diet and injected with SOD3 had
minimal signs of inﬁltrate (Cui et al., 2014). Activated F4/80+/
CD11c+ macrophages form these crown-like structures and leads to
the remodeling and expansion of adipose tissue (Sun et al., 2011).
The mRNA levels of obesity-related inﬂammation genes like F4/80,
TNFa, CD11c, MCP1 and IL6 were lower in these SOD3administered mice and hepatic de novo lipogenesis genes like
SREBP1c, fatty acid synthase and Scd1 were higher in mice that
were just given a high fat diet (Cui et al., 2014).

obese phenotype and associated comorbidities including
cardiovascular diseases, NAFLD/NASH and T2DM. We
demonstrate that obesity propagates cellular oxidative stress
and the activation of a multitude of inﬂammatory signaling
cascades that exacerbate the pathophysiological condition.
Obesity mediated induction of oxidative stress promotes a shift
from physiological homeostasis to favor physical proﬁles
associated with metabolic syndrome. This shift leads to
perturbations that include alterations within the phenotypic
expression of adipocytes, cardiovascular damage, insulin
resistance and abnormal accumulation of triglycerides playing
key roles in the morbidity and mortality associated with obesity.
Such pathological modiﬁcations promote disequilibrium within
the redox state disturbing the functionality of antioxidant
defense mechanisms. These alterations allow for the generation
and sustained action of oxidative free radicals leading to
cytotoxic, inﬂammatory, and apoptotic cascades to be
continually initiated. The typical non-obese phenotype allows for
scavenging of the oxidative radicals reducing the overall potential
for damage. However, the loss of this defense contributes to
developing the chronic inﬂammatory state associated with
obesity. Therefore, the roles of various antioxidants were
addressed for plausible therapeutic applications to improve
clinical outcomes.
The contribution of antioxidants was investigated to
determine their efﬁcacy in attenuating the dysfunctional
phenotype. Given the ease of availability of these antioxidants
as dietary constituents and over-the-counter supplements
enables individuals to reap the beneﬁts at minimal cost. This
offers an optimal potential therapy for the obese population to
slow the development of the obese phenotype. Not surprisingly,
the expression of these antioxidants seems to be reduced across
in vitro or in vivo models and in obese individuals. This provides
speculation that widespread oxidative free radicals may be a
major contributor to the progression of the pathophysiology
associated with obesity and the potential need for antioxidant
supplementation in the obese population.
The actions of these antioxidants have a hallmark trait of
being able to scavenge ROS reducing oxidative stress (Figure 2).
Each individual antioxidant has its own characteristic
mechanism to counteract the pathological environment based
on their physical and chemical properties. For instance, the
lipophilicity of aT and carotenoids enable them to elicit more
beneﬁcial effects within lipid membranes and lipoproteins
compared to others. Some of these antioxidants were able to
act through indirect and direct mechanisms allowing for the
potential to act across various pathways such as HO-1, NAC,
various polyphenols and carotenoids. Although there is a long
list of endogenous and exogenous antioxidants that have been
investigated previously to scavenge free radicals, however, the
mechanistic action of each antioxidant is distinct in terms of the
pathways they inhibit or stimulate. The speciﬁc properties of
each antioxidant, listed in this review, provides insight into
uncovering a link between which obesity induced metabolic
dysfunction they are individually able to respond to optimally,
hence these antioxidants were chosen for review. In the case of

CONCLUSION
This review aims to highlight the therapeutic potential of seven
antioxidants and their mechanistic actions in ameliorating the
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hypertension, it could be argued that many of the antioxidants
may serve a cardioprotective role that is equivalent to each other.
However, for hypertension and hyperglycemic conditions one
may beneﬁt more from antioxidants that promote insulin
sensitivity and lowered blood pressure such as HO-1.
Furthermore, many of the antioxidants may serve a role
working in concert with one another promoting a synergistic
effect across multiple signaling and inﬂammatory cascades
that may attenuate obese phenotypes more-so than one
individual antioxidant.
Primarily, the mechanistic actions of each individual
antioxidant favored normalization within the inﬂammatory
responses encouraging the progression toward non-obese
phenotypes. By acting through inﬂammatory cascades such as
PKC and NF-kb, these antioxidants serve to reduce the levels of
various inﬂammatory mediators including TNF-a, IL-1 b,
VCAM-1, and IL-6 (Carlsen et al., 2009; Kirmizis and
Chatzidimitriou, 2009; Burgess et al., 2010; Rizvi et al., 2014;
Lee and Han, 2018). Furthermore, antioxidants restore the shift
in redox state during altered thermogenesis under diseased
metabolic conditions (Wood Dos Santos et al., 2018). The
antioxidants, like polyphenols and carotenoids, through
induction of thermogenesis, improves the expression of
thermogenic markers like UCP1, hence improving the overall
mitochondrial function and redox imbalance (Wood Dos Santos
et al., 2018). In addition, the activity of proliferative and
differentiative cascades within adipocytes were improved
leading to ameliorated expressions of PPARg and C/EBPa
(Schwarz et al., 1997; Calzadilla et al., 2011; Cao et al., 2012;
Khitan et al., 2014; Springer and Moco, 2019). These effects

resulted in a multitude of improvements including enhanced
insulin sensitivity, adipocyte functionality, reduced circulating
triglycerides, adipogenesis and fat mass (as summarized in Table
1). This infers that each antioxidant has the capability to
attenuate the development and progression of associated
comorbidities through their own mechanisms. Thus, indicating
that there may be a strong relationship between antioxidant
action and alleviating obesity induced oxidative damage and
metabolic dysfunction. The various roles that antioxidants
possess may provide a key to unlocking the optimal therapy
for the pathophysiology of obesity. More research is required to
determine the efﬁcacy of antioxidants working in concert with
one another and with current pharmacotherapy in preventing/
reverting associated comorbidities of obesity.
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